INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified data

Kelly Jason R sold DNA

Director, See remarks · Ginkgo Bioworks Holdings, Inc. · Class A Common Stock

Side
SELL
Value
$463K
Shares
45.7K
Price
$10.14
Executed
Oct 19, 2026
Disclosed
Oct 21, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 19 executedOct 21, 2026 disclosed

DNA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
50/ 100 · NOTABLE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+15 / 25

    $463K reported value · 26.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DNA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    19
    KR
    Kelly Jason RDirector, See remarks
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    25.8K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    32
    CP
    Coen Steven P.See remarks
    DNAGinkgo Bioworks Holdings, Inc.
    Open-market sale
    		SELL$7,770
    766 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    19
    CP
    Coen Steven P.See remarks
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    1,174 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    39
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Open-market sale
    		SELL$191K
    18.8K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    11
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    9,762 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    15
    CP
    Coen Steven P.See remarks
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    312 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    39
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Open-market sale
    		SELL$191K
    18.8K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    35
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Open-market sale
    		SELL$227K
    22.4K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    15
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    26.8K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    29.3K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    15
    SP
    Shetty Reshma P.Director, See remarks, 10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    10.6K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    CP
    Coen Steven P.See remarks
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    312 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    15
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    26.8K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    9,762 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    15
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    29.3K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    10.6K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    35
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Open-market sale
    		SELL$227K
    22.4K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    11
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    26.8K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    15
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    9,762 sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    CB
    Canton Barry10% Owner
    DNAGinkgo Bioworks Holdings, Inc.
    Option exercise
    		M—
    29.3K sh
    		Oct 16, 2026Oct 21, 2026
    traded Oct 16, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-066703
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 19, 2026
    Published
    Oct 21, 2026
    Ingested by INSIDER
    Nov 5, 02:10 UTC
    Last re-read
    Nov 5, 02:10 UTC

    Extracted facts

    Filer
    Kelly Jason R
    Role
    Director, See remarks
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Ginkgo Bioworks Holdings, Inc.
    Ticker
    DNA
    Shares
    45.7K
    Price per share
    $10.14
    Value
    $463,353
    Execution date (reported)
    Oct 19, 2026
    Owned after transaction
    129.1K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 45.7K
    • Price: $10.143

    = $463,353

    What this establishes

    Kelly Jason R filed this Form 4 reporting a open-market sale of DNA on Oct 19, 2026. It became public on Oct 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, See remarks
    Kelly Jason Rcik:0001845677
    Issuer
    Ginkgo Bioworks Holdings, Inc.cik:0001830214

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.